Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer - Abstract

PURPOSE: Stereotactic body radiation therapy (SBRT) is a treatment option for patients with localized prostate cancer, with reported clinical and health-related quality-of-life (QOL) outcomes comparable to standard fractionation radiation therapy.

The goal of this study was to evaluate correlations between short-term QOL outcomes and dosimetric parameters to guide future prostate SBRT planning.

METHODS AND MATERIALS: From 2010 to 2013, QOL data were prospectively collected from 75 patients enrolled in a prostate SBRT clinical trial. A comparison was made between Expanded Prostate Cancer Index Composite scores for patients with the top 25th percentile versus the bottom 75th percentile of the following dose-volume histogram parameters: planning target volume V100; bladder V50 and V100; and rectum V50, V80, V90, and V100. A linear mixed-effect model was used to estimate the difference between the 2 strata for each parameter.

RESULTS: Median follow-up was 12 months. Patients with planning target volume V100 volumes >120 cm3 had the worst reduction in urinary QOL. Urinary QOL was also decreased significantly in patients with bladder V100 volumes >5.5 cm3. Bowel QOL was decreased significantly in patients with rectal V90 and V100 volumes >4.2 and >1.5 cm3, respectively.

CONCLUSIONS: Patients with large prostate size or large volumes of rectum and bladder that receive ≥90% of the prescribed radiation dose are more susceptible to short-term QOL decrements after prostate SBRT. These volumes should be minimized to maximize recovery to baseline QOL after prostate SBRT.

Written by:
Gomez CL, Xu X, Qi XS, Wang PC, Kupelian P, Steinberg M, King CR.   Are you the author?
Department of Radiation Oncology, University of California, Los Angeles, California; Department of Epidemiology, University of California, Los Angeles, California; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California.

Reference: Pract Radiat Oncol. 2015 Mar 3. pii: S1879-8500(15)00010-7.
doi: 10.1016/j.prro.2015.01.006

PubMed Abstract
PMID: 25749214 Prostate Cancer Section